Dec 04, 2019 / 01:30PM GMT
Operator
Good morning, and welcome to today's conference for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for 1 week from today.
I'll turn the call over to Peter Cancelmo, General Counsel for Omeros.
Peter B. Cancelmo - Omeros Corporation - VP, General Counsel & Corporate Secretary
Good morning, and thank you for joining today to discuss data from our pivotal clinical trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, which we will refer to today as stem cell TMA. These data were announced this morning via press release. The press release as well as the slide presentation accompanying this morning's call are available on our website at www.omeros.com.
I'd like to remind you that some of the statements that will be made on today's call will be forward-looking. These forward-looking statements
Omeros Corporation - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot